Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms

Gómez-Gómez,Yazmín; Organista-Nava,Jorge; Saavedra-Herrera,Mónica   Virginia; Rivera-Ramírez,Ana   Bertha; Terán-Porcayo,Marco   Antonio; Alarcón-Romero,Luz  del Carmen; Illades-Aguiar,Berenice; Leyva-Vázquez,Marco   Antonio

doi:10.3892/etm.2012.447

Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms

Authors:
- Yazmín Gómez-Gómez
- Jorge Organista-Nava
- Mónica Virginia Saavedra-Herrera
- Ana Bertha Rivera-Ramírez
- Marco Antonio Terán-Porcayo
- Luz del Carmen Alarcón-Romero
- Berenice Illades-Aguiar
- Marco Antonio Leyva-Vázquez
View Affiliations

Affiliations: Laboratory of Molecular Biomedicine, School of Biological Sciences, Guerrero State University, Chilpanginco, Guerrero, Mexico, Department of Pediatric Oncology, ‘Arturo Beltrán Ortega’ Cancer Institute, Acapulco, Guerrero, Mexico, Laboratory of Cytopathology, School of Biological Sciences, Guerrero State University, Chilpanginco, Guerrero, Mexico
Published online on: January 9, 2012 https://doi.org/10.3892/etm.2012.447
Pages: 665-672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dihydrofolate reductase (DHFR) is the major target of methotrexate, a key component in childhood acute lymphoblastic leukemia (ALL) treatment. Polymorphisms in the gene coding for DHFR have been associated with adverse event treatment. This study evaluated the effect of the -A317G and C829T polymorphisms in the DHFR gene on survival and risk of relapse of ALL. Seventy patients with ALL and 100 healthy individuals were genotyped by the polymerase chain reaction-restriction fragment length polymorphism method. An association between the polymorphisms and the risk of relapse was found (p<0.05); patients with the -317G/G genotype were found to have an 8.55 (95% CI 1.84‑39.70) higher chance of relapse and carriers of the 829T/T genotype had a 14.0 (95% CI 1.13-172.63) higher chance of relapse. Other variables, such as age and leukocyte count, were associated (p<0.05) with the risk of relapse of the disease. Individuals with the G/G and T/T genotype of the -A317G and C829T polymorphisms had poorer survival compared to other genotype groups (log-rank test; p<0.05). Although preliminary, these data seem to suggest a role for the DHFR polymorphisms in the risk of relapse of ALL and the mortality risk in these patients.

View Figures

View References

1.	Coronel-Morán QR: Importancia del laboratorio en el diagnóstico y pronóstico de leucemia aguda linfoblástica de la infancia. Acta Pediátrica de México. 26:129–136. 2005.
2.	Mejia-Arangure JM, Bonilla M, Lorenzana R, et al: Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer. 5:332005. View Article : Google Scholar : PubMed/NCBI
3.	Salud/INEGI, S.d., Fuente: base de datos de defunciones INEGI/Secretaria de Salud, Dirección General de Información en Salud, México. Información disponible en URL https://www.inegi.org.mx/ (Accessed April, 2008).
4.	Cheok MH and Evans WE: Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 6:117–129. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Hider SL, Bruce IN and Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 46:1520–1524. 2007. View Article : Google Scholar
6.	Wang L, Goodey NM, Benkovic SJ and Kohen A: Coordinated effects of distal mutations on environmentally coupled tunneling in dihydrofolate reductase. Proc Natl Acad Sci USA. 103:15753–15758. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Volpato JP, Fossati E and Pelletier JN: Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase. J Mol Biol. 373:599–611. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Allemann RK, Evans RM, Tey LH, et al: Protein motions during catalysis by dihydrofolate reductases. Philos Trans R Soc Lond B Biol Sci. 361:1317–1321. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Fotoohi AK: Resistance of human leukaemia cells to the antimetabolites. Oncology-Pathology, Suecia. 1:1–84. 2007.
10.	Serra M, Reverter-Branchat G, Maurici D, et al: Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol. 5:151–160. 2004. View Article : Google Scholar
11.	De Jonge R, Hooijberg JH, van Zelst BD, et al: Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood. 106:717–720. 2005.PubMed/NCBI
12.	Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26:153–181. 2007. View Article : Google Scholar
13.	Goto Y, Yue L, Yokoi A, et al: A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res. 7:1952–1956. 2001.
14.	Dulucq S, St-Onge G, Gagne V, et al: DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood. 111:3692–3700. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Seguro-popular: Secretaria de Salud/Seguro Popular, Información disponible en URL http://www.seguro-popular.salud.gob.mx/uri (Accessed May, 2009).
16.	Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 84:3122–3133. 1994.PubMed/NCBI
17.	Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 14:18–24. 1996.PubMed/NCBI
18.	Merante F, Raha S, Reed JK and Proteau G: The simultaneous isolation of RNA and DNA from tissues and cultured cells. Methods Mol Biol. 58:3–9. 1996.PubMed/NCBI
19.	Organista-Nava J, Gómez-Gómez Y, Saavedra-Herrera MV, et al: Polymorphisms of the γ-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leukemia Res. 34:728–732. 2010.
20.	Kooloos WM, Wessels JAM, van der Straaten T, Allaart CF, Huizinga TWJ and Guchelaar HJ: Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics. 11:163–175. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Gellekink H, Blom HJ, van der Linden IJ and den Heijer M: Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels. Eur J Hum Genet. 15:103–109. 2007. View Article : Google Scholar
22.	Mishra PJ, Longo GSA, Menon LG, Abali EE, Humeniuk R, Cole PD, Kamen BA, Banerjee D and Bertino JR: The 829C-T single nucleotide polymorphism in the 30 UTR of the dihydrofolate reductase gene results in methotrexate resistance and is rare among non-Japanese American patients. Proc Amer Assoc Cancer Res. 301:12742006.
23.	Parle-McDermott A, Pangilinan F, Mills JL, et al: The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet Part A. 143:1174–1180. 2007. View Article : Google Scholar
24.	Ng SM, Lin HP, Ariffin WA, Zainab AK, Lam SK and Chan LL: Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol. J Trop Pediatr. 46:338–343. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Frankel LS, Ochs J, Shuster JJ, et al: Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol. 19:351997. View Article : Google Scholar : PubMed/NCBI
26.	Shuster JJ, Wacker P, Pullen J, et al: Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 16:2854–2863. 1998.PubMed/NCBI
27.	Kim K, Kang SB, Chung HH, Kim JW, Park NH and Song YS: XRCC1 Arginine 194 Tryptophan and GGH-401 Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 111:509–515. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Dervieux T, Greenstein N and Kremer J: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54:3095–3103. 2006. View Article : Google Scholar : PubMed/NCBI
29.	Chessells JM, Veys P, Kempski H, et al: Long term follow up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol. 123:396–405. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Chen SH, Yang CP, Hung IJ, Jaing TH, Shih LY and Tsai MH: Clinical features, molecular diagnosis, and treatment outcome of infants with leukemia in Taiwan. Pediatr Blood Cancer. 55:1264–1271. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Daniel-Cravioto A, Gonzalez-Bonilla CR, Mejia-Arangure JM, et al: Genetic rearrangement MLL/AF4 is most frequent in children with acute lymphoblastic leukemias in Mexico City. Leuk Lymphoma. 50:1352–1360. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Bernaldez-Rios R, Ortega-Alvarez MC, Perez-Saldivar ML, Alatoma-Medina NE and del Campo-Martinez M: The age incidence of childhood B-cell precursor acute lymphoblastic leukemia in Mexico City. J Pediatr Hematol/Oncol. 30:199–203. 2008. View Article : Google Scholar : PubMed/NCBI